Vyriad, Imanis Ink Cancer Companion Dx Development Deal

Aug 16, 2016

|

NEW YORK (GenomeWeb) – Vyriad announced today that it has partnered with Imanis Life Sciences to develop in vitro and in vivo tests to predict a patient's likelihood of responding to its oncolytic virus therapeutics.

Vyriad is developing cancer treatments that use vesicular stomatitis and measles viruses modified with genes encoding known tumor antigens in order to trigger anticancer immune responses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

Recent Headlines from
Precision Oncology News

The Scan

Genes at the Mall Near You?

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

Koalas' Retroviral Response

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

Bound for Home

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

Science Paper Peers into Ancient Social Inequality Within Households

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.

Featured White Papers

Analytical Validation of the Oncomine Pan-Cancer Cell-Free Assay

Multiplexed Infectious Disease Analysis

A High-Performance Solution Combining CleanPlex OncoZoom Cancer Hotspot Panel and SOPHiA AI for Rapid Characterization of Somatic Mutations

Benchmarking of the Microsart AMP Mycoplasma Kit with Products of Two Other Suppliers

Oct

21

Featured Webinar

Broad Genomic Testing for Oncology Clinical Trials and Clinical Practice

Genomics is a key element in the potential of precision medicine to transform oncology.

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Oct

24

Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov

04

Featured Webinar

Digital Solutions for NGS Genotyping – Accuracy, Clinical Relevancy, and Report Generation

This webinar will provide a look at how the Institute of Hematopathology in Hamburg, Germany, is implementing complex genomic testing for lung cancer.

Menu